S-OIV (SWINE ORIGIN INFLUENZA VIRUS)

Team members

Shabana

Priyadarsini.suresh

Dr.R. Saraswati Jayanthi

Himanshu

Content:

Introduction Hazard Identification Dose Response Exposure Assessment Risk Characterization Conclusion References

Introduction: Acute respiratory illness due to influenza viruses

are the major causes of morbidity and mortality in early childhood

The first case of swine flu was reported in April 2009 ever since that day the virus has spread rapidly

Hazard Identification: The influenza virion is roughly spherical. It is an enveloped virus. Inserted into the envelope are two proteins HA &

NA, that determine the subtype of influenza virus for example A/H1N1

There are many subtypes of influenza A known as H1N1, H1N2, H2N1, H3N1, H3N2, and H2N3

The recent pandemic H1N1 virus which emerged in 2009 in Mexico and spread worldwide is a reassortment of 3 or 4 virus strains i.e American swine, Eurasian swine, North American avian and human influenza virus strains

The incubation period for swine influenza infection appears to range from 2 to 7 days

Most patients with swine influenza infection might shed virus from 1 day before the onset of symptoms through 5 to 7 days after the onset of symptoms or until symptoms resolve

In young children and in immunocompromised or severely ill patients, the infectious period might be longer

The most common symptoms are:

Fever cough Sore throat Running nose

Body acheHead achefatigue

Patients susceptible to severe disease are

- children's(below 5 years)

- Elderly persons (above 60)

- Pregnant women

-Those with systemic illnesses ,immune suppressed

YEAR CASES DEATHS

2009 27236 981

2010 20604 1763

2011 603 75

2012 5044 405

2013 5253 405

2014 937 218

2015 31974 1895

Dose Response

The existing dose response model shown below in the table was used in this study.

Experiment serial

number

Host type

Agent strain

Route# of

dosesDose units

Response

Best fit model

Optimized

parameter(s)

LD50/

ID50

257, 258*

Human

H1N1,A/

California/10/78 attenuat

ed strain, 

intranasal

9 TCID50

infection

beta-Poisson

α = 5.81E-

01 , N50=9.4

5E+05

9.45E+05

Exposure Assessment

This risk assessment can be broken down into two basic parts:

The risk analysis due to the intranasal exposure of higher concentration of influenza virus

The risk analysis due to intranasal exposure of lower range concentration

RISK CHARACTERISATION

Age P(DAILY risk of infection) P (risk of illness)

P (Risk of mortality)

3 to <6 1.06E-06 0.0000 1.05103E-07

6 to<11 1.33E-01 0.0596 0.0131

16 to <21 2.12E-02 0.0095 0.00209

41 to <55 1.72E-01 0.0773 0.017008

61 to <71 1.49E-01 0.0668 0.014703

Risk due to the lower dose range

RISK CHARACTERISATION

Risk due to the higher dose range

Age P(response) P(DAILY risk of infection)

P (risk of illness)

P (Risk of mortality)

3 to <6 6.46E-01 1.35E-04 0.0001 1.33315E-05

6 to<11 7.12E-01 1.61E-04 0.0001 1.5945E-05

16 to <21 8.16E-01 2.19E-04 0.0001 2.17295E-05

41 to <55 8.21E-01 2.23E-04 0.0001 2.20383E-05

61 to <71 7.61E-01 1.85E-04 0.0001 1.83326E-05

Risk Management:

Keeping distance from infected patients Visit a doctor as soon as you see the

symptoms

Washing hand

Wearing mask

Use hand sanitizers

CONCLUSION:

It is important to consider that the risk of acquiring influenza is

determined by both the concentration of the influenza A virus infectious

particles in the air and the immune status of the exposed individuals.

It is important to consider that the air exhaled by the healthy person

also contains influenza virus particles.

THANK YOU